Hikma Slams Amarin In Vascepa Antitrust Suit For ‘Locking Up API Supply’

Fellow Icosapent ANDA Sponsor Dr Reddy’s Also Previously Filed Antitrust Suit

 
• By Dean Rudge
  
Generate a summary of this article
Listen to this article
Beta

Amarin is facing up to another antitrust lawsuit over its alleged control of API supply for its Vascepa brand.

Antitrust law - Image
• Source: Shutterstock

Hikma has filed an antitrust suit against Amarin in a federal district court in New Jersey, accusing the originator of anticompetitive conduct to “prevent, delay, and frustrate” generic competition to its Vascepa (icosapent ethyl) purified fish oil brand, following much dialog around generic manufacturers’ ability to source enough of the active pharmaceutical ingredient to mount a material charge.

“Amarin deliberately and meticulously locked up the supply of API icosapent ethyl, in excess of its own needs, in order...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Generics

Amneal Kicks Off China Business With First Approval

Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

Nichi-Iko Warns Over Delays From Toyama Plant

Nichi-Iko says that remediation activities at its Toyama plant in the wake of a suspension over GMP violations mean that there may be delays to supply.

More from Products

Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

Nichi-Iko Has An Ally In Argentina On Infliximab

Laboratorio Elea has struck a deal with Nichi-Iko Pharmaceutical to market the Japanese firm’s infliximab biosimilar in Argentina.

Biocon Biologics Refreshes Management

Biocon has made two key appointments to the management team of Biocon Biologics following a recent change in CEO for the biosimilars business.